In a significant move to address the rising burden of non-communicable diseases (NCDs), C&D Pharma, an Indian pharmaceutical innovator, has launched three advanced therapies in the Ugandan market. The new treatments, unveiled at a symposium in Kampala, aim to improve access to affordable, effective solutions for conditions like hypertension, diabetes, kidney disease, and cardiovascular disease, which continue to strain Uganda’s healthcare system.
The products introduced include Cliniplan Trio, Dairetin Family, and Daptide—innovative, fourth-generation therapies designed to tackle chronic diseases that are increasingly prevalent across the country. Cliniplan Trio is a combination therapy specifically for managing high blood pressure, while protecting vital organs such as the heart, kidneys, and eyes. Dairetin Family, which comprises Diatrin M and Diatrin Trio, represents a breakthrough in diabetic care, offering better blood sugar control and reducing the risk of long-term complications. Daptide targets both diabetes and hypertension, providing precise management to prevent complications affecting the heart and kidneys.
Speaking at the launch, Dr. Charles Olaro, Uganda’s Director of Curative Services at the Ministry of Health, underscored the urgency of addressing the NCD crisis, particularly in rural and underserved regions. He noted that Uganda faces a significant health burden due to these diseases, and the introduction of such treatments is a step forward in reducing the strain on the country’s healthcare resources.
“The burden of non-communicable diseases, especially in rural and hard-to-reach areas, demands innovative solutions,” said Dr. Olaro. “We need treatments that not only manage the symptoms but also prevent the long-term complications that often overwhelm our healthcare system.”
The launch event, held with support from the Ministry of Health, Joint Medical Stores (JMS), and KAMCARE, highlighted the collaborative effort to reach even the most remote communities in Uganda. The new therapies are expected to alleviate the pill burden on patients and reduce the financial strain on families, as well as support the broader effort of achieving health equity across the country.
Chirag Vora, Managing Director of C&D Pharma, expressed confidence in the impact of the therapies, emphasizing that their introduction would help reduce the need for emergency care and long-term hospitalizations. “These therapies will not only improve the health outcomes of patients but also reduce the strain on our healthcare infrastructure, leading to better resource allocation,” Vora said.
The Ugandan government, along with healthcare partners, is committed to ensuring these advanced therapies reach the country’s most vulnerable populations, further strengthening the nation’s healthcare system.
